Published in Virology on June 27, 2007
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol (2010) 2.25
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol (2010) 1.26
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13
Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One (2009) 1.08
An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc (2010) 1.07
Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology (2008) 1.07
Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal Immunol (2011) 1.05
Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol (2009) 1.04
A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther (2010) 1.03
A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther (2009) 1.00
Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol (2009) 0.96
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology (2015) 0.96
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol (2013) 0.95
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci (2009) 0.90
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol (2012) 0.88
Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol (2010) 0.86
Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther (2011) 0.85
Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Front Immunol (2014) 0.81
Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. Vaccine (2016) 0.75
Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses. Vaccine (2016) 0.75
The Use of Adenovirus Dodecahedron in the Delivery of an Enzymatic Activity in the Cell. Biotechnol Res Int (2016) 0.75
Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses. PLoS Comput Biol (2016) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol (2003) 15.51
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Immunological memory and protective immunity: understanding their relation. Science (1996) 10.02
Programmed contraction of CD8(+) T cells after infection. Nat Immunol (2002) 5.16
Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol (2006) 3.29
Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol (1997) 3.28
Lymphocyte life-span and memory. Science (1994) 2.99
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. J Exp Med (2006) 2.80
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol (2006) 2.47
Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol (2002) 2.31
Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol (1999) 1.99
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol (2003) 1.75
T cell death and memory. Science (2001) 1.74
Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev (2006) 1.72
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005) 1.63
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol (2005) 1.45
Migration and differentiation of CD8+ T cells. Immunol Rev (2002) 1.41
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol (2004) 1.33
Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells. Eur J Immunol (2006) 1.25
Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine (2000) 1.15
Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol (2002) 1.07
CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther (2004) 1.02
Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol (2003) 1.01
Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine (2006) 0.87
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity (2003) 6.19
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol (2005) 2.87
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol (2005) 2.48
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol (2002) 2.31
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007) 2.21
Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med (2002) 2.20
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood (2006) 1.94
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med (2005) 1.85
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med (2009) 1.82
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol (2003) 1.75
The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines (2004) 1.71
Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr (2007) 1.71
Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest (2003) 1.69
Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. J Virol (2009) 1.65
Management of rabies in humans. Clin Infect Dis (2002) 1.64
Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther (2005) 1.63
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 1.57
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood (2011) 1.56
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol (2008) 1.50
Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J Immunol (2007) 1.50
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther (2009) 1.49
Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest (2004) 1.48
Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis (2004) 1.46
Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virus. J Virol (2002) 1.46
Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol (2002) 1.38
Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol (2005) 1.29
Roles of target cells and virus-specific cellular immunity in primary simian immunodeficiency virus infection. J Virol (2004) 1.29
A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol (2003) 1.28
Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine (2010) 1.27
Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol (2005) 1.27
Defective CD8 T cell responses in aged mice are due to quantitative and qualitative changes in virus-specific precursors. J Immunol (2012) 1.25
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine (2009) 1.24
Cell-intrinsic defects in the proliferative response of antiviral memory CD8 T cells in aged mice upon secondary infection. J Immunol (2010) 1.21
Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol (2009) 1.19
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther (2007) 1.18
Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol Ther (2011) 1.18
Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol (2006) 1.17
Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape. J Virol (2007) 1.14
Vertical distance from the crest of bone to the height of the interproximal papilla between adjacent implants. J Periodontol (2003) 1.14
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol (2008) 1.12
Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol (2010) 1.10
Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev (2012) 1.09
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology (2010) 1.07
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med (2008) 1.07
Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol (2003) 1.07
Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog (2011) 1.06
Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol (2009) 1.04
A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther (2010) 1.03
HIV escape: there and back again. Nat Med (2004) 1.03
Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther (2010) 1.02
A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther (2006) 1.00
A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther (2009) 1.00
Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol (2010) 0.99
Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol (2009) 0.99
Viruses - from pathogens to vaccine carriers. Curr Opin Virol (2011) 0.96
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther (2007) 0.96
Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J Immunol (2003) 0.95
A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res (2002) 0.95
Timing, positioning, and sequential staging in esthetic implant therapy: a four-dimensional perspective. Int J Periodontics Restorative Dent (2007) 0.95
Immune barriers to successful gene therapy. Trends Mol Med (2008) 0.93
Caffeine consumption during pregnancy and risk of preterm birth: a meta-analysis. Am J Clin Nutr (2010) 0.92
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One (2009) 0.90
Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Vaccine (2013) 0.90
Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci (2009) 0.90
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS (2003) 0.89
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med (2014) 0.89
A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther (2003) 0.88
Pandemic influenza vaccines. Curr Top Microbiol Immunol (2009) 0.88
Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J Leukoc Biol (2009) 0.87
Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Curr Opin HIV AIDS (2010) 0.87
Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87
Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J Immunol (2011) 0.87